Feng Liu
5 Papers
2 Citations
Feng Liu is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Nan Wang,Yan Zhan,Linyu Zhu,Zhibing Hou,Feng Liu,Pinhong Song,Feng Qiu,Xiaolin Wang,Xiafei Zou,Deyun Wan,Xiaosong Qian,Shanshan Wang,Yabi Guo,Hao Yu,Miao Cui,Gangling Tong,Yunsheng Xu,Zhihua Zheng,Yingying Lu,Peng Hong,Peng Hong,Peng Hong +21 more
TL;DR: It is concluded that administration of IFN-α2b during the early stage of COVID-19 may induce favorable clinical responses and reduce mortality and accelerated recovery compared to lopinavir/ritonavir (LPV/r) alone.
295
94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
TL;DR: A Phase 1 multiple-ascending dose study of RGT-075 in adults with type 2 diabetes (T2DM) up to 28 days was safe and QD dosing showed promising exploratory efficacy trends despite high baseline variability and short treatment duration.
2
753-P: RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models
TL;DR: In food-induced glucose intolerant and prediabetic cynomolgus monkeys, oral administration of RGT-075 improved glucose tolerance to a level comparable to injectable liraglutide and support the development and advancement of R GT-075 into the clinic as a potential therapeutic for T2D and obesity.
1
724-P: A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects
TL;DR: Overall, single RGT-075 doses between 15-280 mg were safe and well-tolerated in healthy volunteers, and further clinical development of R GT-075 as a once-daily, oral therapy for T2DM is underway.
1
Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.
Yingying Lu,Feng Liu,Gangling Tong,Feng Qiu,Pinhong Song,Xiaolin Wang,Xiafei Zou,Deyun Wan,Miao Cui,Yunsheng Xu,Zhihua Zheng,Peng Hong,Peng Hong,Peng Hong +13 more
TL;DR: In this article, a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids was retrospectively analyzed.